Alto Neuroscience, Inc. reported full year 2025 financial results, including net loss of $63.2 million compared to $61.4 million in 2024, and cash, cash equivalents, and restricted cash of $177 million as of December 31, 2025, expected to fund operations into 2028. The company provided business highlights on ALTO-207 acquisition for treatment-resistant depression and upcoming clinical trial milestones across its pipeline.
Key takeaways
Net loss of $63.2 million for year ended December 31, 2025 vs. $61.4 million in 2024
Cash, cash equivalents, and restricted cash of $177 million as of December 31, 2025, vs. $169 million as of December 31, 2024, expected to fund operations into 2028
Acquired ALTO-207 in June 2025 for TRD; Phase 2b trial initiation planned for first half of 2026 with topline data in second half of 2027
ALTO-101 granted FDA Fast Track Designation; topline Phase 2 POC data for CIAS expected around end of 1Q 2026
ALTO-300 Phase 2b MDD topline data expected mid-2026; ALTO-100 Phase 2b BPD topline data expected 2H 2026